Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Melanoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 28Nivolumab 13Carboplatin 9fludarabine 7Paclitaxel 7Gemcitabine 7Docetaxel 7Cyclophosphamide 7Cisplatin 7Trastuzumab 5palbociclib 4cemiplimab 4avelumab 4atezolizumab 4Ipilimumab 4Fluorouracil 4Filgrastim 4Drug Therapy 4Cetuximab 4fludarabine phosphate 3epacadostat 3durvalumab 3Taxes 3Oxaliplatin 3Fulvestrant 3zimberelimab 2ulixertinib 2trametinib 2tisotumab vedotin 2spartalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × pexidartinib × Head & Neck × Clear all
NCT02452424 2020-03-05

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Daiichi Sankyo

Phase 1/2 Terminated
78 enrolled 19 charts
DermatologicGastrointestinalGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡